Try
OPKO Health Inc. Common Stock
OPKUnited States
5 filed reports · 368 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 39 commentary passages.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 2 | 574 | Jun 2025 to Sep 2025 |
| Quarterly · 10-Q/ASEC EDGAR | 2 | 936 | Mar 2026 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 1,265 | Dec 2025 |
Financial data
368 concepts · 2,775 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial348 concepts · 2,193 facts · Mar 2023 to Jun 2026
- Stockholders equity (US GAAP)14 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations13 · Dec 2023 to Jun 2026
- Earnings per share basic13 · Dec 2023 to Jun 2026
- Earnings per share diluted13 · Dec 2023 to Jun 2026
- Net income loss13 · Dec 2023 to Jun 2026
- Revenue13 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value12 · Dec 2023 to Jun 2026
- Amortization of intangible assets12 · Dec 2023 to Jun 2026
- Comprehensive income net of tax12 · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)12 · Dec 2023 to Jun 2026
- Costs and expenses12 · Dec 2023 to Jun 2026
- Depreciation12 · Dec 2023 to Jun 2026
- Depreciation depletion and amortization12 · Dec 2023 to Jun 2026
- Foreign currency transaction gain loss before tax12 · Dec 2023 to Jun 2026
- Gain loss on derivative instruments net pretax12 · Dec 2023 to Jun 2026
- Gross profit (US GAAP)12 · Dec 2023 to Jun 2026
- Income loss from equity method investments12 · Dec 2023 to Jun 2026
- Income tax expense benefit12 · Dec 2023 to Jun 2026
- Interest expense nonoperating12 · Dec 2023 to Jun 2026
- Inventory write down12 · Dec 2023 to Jun 2026
- Investment income interest12 · Dec 2023 to Jun 2026
- Nonoperating income expense12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent12 · Dec 2023 to Jun 2026
Segment12 concepts · 369 facts · Dec 2023 to Jun 2026
- Revenue72 · Dec 2023 to Jun 2026
- Goodwill foreign currency translation gain loss66 · Dec 2024 to Jun 2026
- Goodwill, acquired (disposed of)44 · Dec 2024 to Dec 2025
- Amortization of intangible assets24 · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)24 · Dec 2023 to Jun 2026
- Depreciation depletion and amortization24 · Dec 2023 to Jun 2026
- Gross profit (US GAAP)24 · Dec 2023 to Jun 2026
- Operating income loss24 · Dec 2023 to Jun 2026
- Research and development expense24 · Dec 2023 to Jun 2026
- Selling general and administrative expense24 · Dec 2023 to Jun 2026
- Segment reporting other item amount18 · Dec 2023 to Jun 2026
- Impairment of long lived assets held for use1 · Dec 2025
Product7 concepts · 129 facts · Dec 2023 to Jun 2026
- Revenue55 · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)24 · Dec 2023 to Jun 2026
- Contract with customer liability revenue recognized12 · Dec 2023 to Jun 2026
- Valuation allowances and reserves charged to cost and expense12 · Dec 2023 to Jun 2026
- Valuation allowances and reserves deductions12 · Dec 2023 to Jun 2026
- Rayaldee10 · Dec 2023 to Jun 2026
- Intellectual Property and Other4 · Jun 2025 to Jun 2026
Geography1 concepts · 84 facts · Dec 2023 to Jun 2026
- Revenue84 · Dec 2023 to Jun 2026
Segments
582 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments2 members · 259 facts
- Pharmaceutical130 · Dec 2023 to Jun 2026
- Diagnostics129 · Dec 2023 to Jun 2026
Product or service5 members · 129 facts
- Rayaldee58 · Dec 2023 to Jun 2026
- Product24 · Dec 2023 to Jun 2026
- Service24 · Dec 2023 to Jun 2026
- Transfer Of Intellectual Property And Other12 · Dec 2023 to Jun 2026
- Intellectual Property And Other11 · Jun 2024 to Jun 2026
Subsegments11 members · 110 facts
- Bioreference10 · Dec 2024 to Jun 2026
- Curna10 · Dec 2024 to Jun 2026
- Finetech10 · Dec 2024 to Jun 2026
- Modex Therapeutics Inc10 · Dec 2024 to Jun 2026
- Opko Biologics10 · Dec 2024 to Jun 2026
- Opko Chile10 · Dec 2024 to Jun 2026
- Opko Diagnostics10 · Dec 2024 to Jun 2026
- Opko Health Europe10 · Dec 2024 to Jun 2026
- Opko Mexico10 · Dec 2024 to Jun 2026
- Rayaldee10 · Dec 2024 to Jun 2026
- Transition Therapeutics10 · Dec 2024 to Jun 2026
Statement geographical7 members · 84 facts
- CL12 · Dec 2023 to Jun 2026
- ES12 · Dec 2023 to Jun 2026
- IE12 · Dec 2023 to Jun 2026
- IL12 · Dec 2023 to Jun 2026
- MX12 · Dec 2023 to Jun 2026
- Other Countries12 · Dec 2023 to Jun 2026
- US12 · Dec 2023 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Management discussion (MD&A) commentary39 claims from 2 reports · Mar 2026 to Jun 2026
Earnings calls
4 calls · Jul 2025 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 27, 2026
- FY2025 Q4Feb 26, 2026
- FY2025 Q3Oct 29, 2025
- FY2025 Q2Jul 31, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.